SHB.B

215.8

+2.57%↑

SWED.A

324.1

+0.5%↑

SCA.A

124.65

+0.36%↑

EVO

598

+3.64%↑

SKF.B

229.8

+3.05%↑

SHB.B

215.8

+2.57%↑

SWED.A

324.1

+0.5%↑

SCA.A

124.65

+0.36%↑

EVO

598

+3.64%↑

SKF.B

229.8

+3.05%↑

SHB.B

215.8

+2.57%↑

SWED.A

324.1

+0.5%↑

SCA.A

124.65

+0.36%↑

EVO

598

+3.64%↑

SKF.B

229.8

+3.05%↑

SHB.B

215.8

+2.57%↑

SWED.A

324.1

+0.5%↑

SCA.A

124.65

+0.36%↑

EVO

598

+3.64%↑

SKF.B

229.8

+3.05%↑

SHB.B

215.8

+2.57%↑

SWED.A

324.1

+0.5%↑

SCA.A

124.65

+0.36%↑

EVO

598

+3.64%↑

SKF.B

229.8

+3.05%↑

Search

Cloetta AB

Open

53.35 0.76

Overview

Share price change

24h

Current

Min

52.8

Max

53.9

Key metrics

By Trading Economics

Income

109M

298M

Sales

54M

2.2B

P/E

Sector Avg

18.13

54.484

EPS

0.8

Dividend yield

2.79

Profit margin

13.357

Employees

2,614

EBITDA

50M

389M

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.79%

4.92%

Next Earnings

6 maj 2026

Market Stats

By TradingEconomics

Market Cap

1.8B

14B

Previous open

52.59

Previous close

53.35

Cloetta AB Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 mar 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Nike, RH, NCino

31 mar 2026, 22:35 UTC

Earnings

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 kwi 2026, 00:00 UTC

Acquisitions, Mergers, Takeovers

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar 2026, 23:50 UTC

Acquisitions, Mergers, Takeovers

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar 2026, 23:33 UTC

Market Talk
Major News Events

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar 2026, 23:21 UTC

Earnings

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar 2026, 23:14 UTC

Market Talk
Earnings

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss Widens >000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar 2026, 21:35 UTC

Earnings

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Earnings

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Earnings

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar 2026, 21:33 UTC

Earnings

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar 2026, 21:32 UTC

Earnings

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar 2026, 21:28 UTC

Earnings

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar 2026, 21:26 UTC

Earnings

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar 2026, 21:25 UTC

Earnings

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar 2026, 21:24 UTC

Market Talk
Earnings

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar 2026, 21:22 UTC

Earnings

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar 2026, 21:22 UTC

Earnings

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar 2026, 21:21 UTC

Earnings

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar 2026, 21:20 UTC

Earnings

Nike CEO: Converse Remains Important to Portfolio

Peer Comparison

Price change

Cloetta AB Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Cloetta AB

Cloetta AB (publ) operates as a confectionary company. It operates through Branded Packaged Products and Pick & Mix segments. The company manufactures and markets chocolate confectionery products, including pralines, chocolate wafers, dragees, plates, and countlines under the Kexchoklad, Polly, Plopp, Tupla, Royal, Sportlunch, Bridge, Lonka, Sinas, and Snippers brands. It also provides confectionery products comprising foams, wine gums, liquorice, toffees, hard boiled candies, and lollypops under the Malaco, Red Band, Ahlgrens bilar, Venco, Chewits, and Juleskum brands. In addition, the company offers pastilles under the Läkerol, Mynthon, and King brands, as well as chewing gums under the Jenkki, Sportlife, and Xylifresh brands. Further, it produces and sells dry roasted nuts under the Nutisal brand. The company sells its products through a network of grocery retail trade, service trade, e-commerce, and other sales channels in Sweden, Finland, the Netherlands, Denmark, Norway, Germany, the United Kingdom, and internationally. Cloetta AB (publ) was founded in 1862 and is headquartered in Sundbyberg, Sweden.
help-icon Live chat